DongKook Pharmaceutical 2026 Q1: Steady Performance and Continued Dividend Policy

Consolidated Q1 revenue KRW 251.0B, operating profit KRW 27.3B, net profit KRW 26.3B (controlling interest KRW 24.9B), EPS KRW 553
Separate revenue KRW 212.4B, operating profit KRW 23.3B, net profit KRW 23.6B, EPS KRW 523
Board resolved approval of FY2025 financial statements and cash dividend (amount undisclosed)
Credit rating A- (NICE, 2026.03.14) maintained
Major products hold high market share: oral disease treatment 56.5%, skin disease treatment 59.6%, etc.
R&D expense KRW 8.7B (4.1% of sales)
Two minor lawsuits pending (trial cancellation KRW 200M, trademark infringement KRW 250M)
Contingent liability: refund obligation recognized for choline alfoscerate clinical re-evaluation
Treasury shares: 119,693 shares (0.26%)
Consolidated assets KRW 1.09T, liabilities KRW 310.7B, equity KRW 780.6B